•
China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have jointly announced a licensing agreement with UK major AstraZeneca (AZ, NASDAQ: AZN) for CMG901, a potential first-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2. AstraZeneca is taking on global development, manufacturing, and commercialization rights to the…
•
China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing round, raising RMB 260 million (USD 37.7 million). This follows the USD 100 million Series D funding secured in July 2021. The latest round was led by Guoxin Investment, with contributions from Trinity Innovation Fund,…
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD 226.2 million) through the private placement of 148 million shares on the Shanghai Stock Exchange. The proceeds will be directed towards the preparation of a digital intelligent manufacturing construction project and an anti-viral active pharmaceutical…
•
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding round was led by Bluerun Ventures and CDH Investments, with participation from Naton Technology and Guokr.com. Company Background and AchievementsFounded in 2019,…
•
China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly secured an undisclosed amount of angel funding. The round was led by Tus Star, with participation from Wuxi Kelin Venture Capital Partnership. The proceeds will be directed towards accelerating the research and development of pelvic…
•
MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over RMB 100 million (USD 14.58 million) in its latest financing round. The round was led by Cathay Biotech Inc. (SHA: 688065), a synthetic biology firm based in Shanghai, with contributions from Lenovo Capital and Sequoia…
•
Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a 60.25% stake in Surgimaster Surgical Co., Ltd, a medical power tool products provider based in Suzhou. The transaction, valued at RMB 11 million (USD 1.6 million), is accompanied by an additional RMB 6.5 million (USD…
•
Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100 million (USD 14.54 million) in a Series A+ financing round. The round was led by Silicon Paradise Asset Management, with additional investments from DT Capital Partners and Qianzhan Investment. The proceeds will be used to…
•
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based in Beijing, has reportedly raised “hundreds of millions” of renminbi in a Series D financing round. This significant funding round was led by In Capital, with contributions from Banyan Pacific Capital, Huajin Capital, Qiandao Investment…
•
China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services provider, has announced the 100% acquisition of compatriot firm Vectoring Pharmatech Ltd. This strategic move is designed to enhance CTI’s business layout in the pharmacy CMC (Chemistry, Manufacturing, and Controls) research field. No financial details…
•
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6 million) in its latest financing round. This significant funding will be used to accelerate clinical studies and regulatory filings for multiple innovative drugs, particularly oral small molecule GLP-1RA drugs, as well as to develop new…
•
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of subject enrollment in a clinical study for its novel adjuvanted recombinant shingles vaccine, REC610. This milestone marks a significant step in the development of a vaccine designed to provide enhanced protection against shingles, particularly for…
•
China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. This significant capital raise was led by Suzhou Industrial Park Development Zhidao Equity Investment Partnership and Qianrong Capital, with additional contributions from Haida Investment. The funds…
•
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. This significant capital injection was led by Linear Venture, with GL Ventures also participating. The funds will be directed towards market filing for an ophthalmic surgery robot, the development of microsurgery robots, and…
•
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and oncology, has announced the completion of a Series D financing round at close to RMB 300 million (USD 44.18 million). This significant funding round was led by Hongfu Investment, with contributions from Jihan Capital, Hainan…
•
Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has announced the completion of a Series A+ financing round in excess of RMB 100 million (USD 14.73 million). The round was led by China Merchants Health, with existing investor Simcere Pharmaceutical Group (HKG: 2096) participating.…
•
Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB 100 million (USD 14.75 million) in a Series A financing round. This significant capital injection will support the company’s efforts to provide solutions better tailored to customer needs globally. Financing DetailsThe Series A round was…
•
China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare Scientific Co., Ltd. This strategic collaboration aims to enhance the development and marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. Partnership DetailsJenscare, based in Ningbo, is focused on…
•
Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards of RMB 100 million (USD 14.74 million) in a Series A financing round. This significant capital injection will support the company’s ongoing efforts in research and development (R&D), pipeline filing and clinical trials, and business…
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering of 40 million shares, priced at RMB 20 (USD 2.95) per share, to the Shenzhen Stock Exchange. This move aims to raise significant capital for the company’s ongoing drug development initiatives. Use of ProceedsThe proceeds…